INHIBRX BIOSCIENCES INC (INBX) Stock Price, Quote, News and Overview
NASDAQ:INBX - Nasdaq - US45720N1037 - Common Stock - Currency: USD
INBX Quote, Performance and Key Statistics
12.56
-0.24 (-1.88%)
The current stock price of INBX is 12.56 USD. In the past month the price decreased by -4.05%. In the past year, price decreased by -67.19%.
INBX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About INBX
Company Profile
Inhibrx Biosciences Inc is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 166 full-time employees. The company went IPO on 2024-05-28. Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Company Info
INHIBRX BIOSCIENCES INC
11025 N. Torrey Pines Road, Suite 140
La Jolla CALIFORNIA 92037 US
CEO: Mark P. Lappe
Employees: 169
Company Website: https://inhibrx.com/
Phone: 18587954220
INHIBRX BIOSCIENCES INC / INBX FAQ
What is the stock price of INHIBRX BIOSCIENCES INC today?
The current stock price of INBX is 12.56 USD. The price decreased by -1.88% in the last trading session.
What is the ticker symbol for INHIBRX BIOSCIENCES INC stock?
The exchange symbol of INHIBRX BIOSCIENCES INC is INBX and it is listed on the Nasdaq exchange.
On which exchange is INBX stock listed?
INBX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for INHIBRX BIOSCIENCES INC stock?
7 analysts have analysed INBX and the average price target is 15.3 USD. This implies a price increase of 21.82% is expected in the next year compared to the current price of 12.56. Check the INHIBRX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is INHIBRX BIOSCIENCES INC worth?
INHIBRX BIOSCIENCES INC (INBX) has a market capitalization of 181.87M USD. This makes INBX a Micro Cap stock.
How many employees does INHIBRX BIOSCIENCES INC have?
INHIBRX BIOSCIENCES INC (INBX) currently has 169 employees.
What are the support and resistance levels for INHIBRX BIOSCIENCES INC (INBX) stock?
INHIBRX BIOSCIENCES INC (INBX) has a support level at 12.42 and a resistance level at 12.83. Check the full technical report for a detailed analysis of INBX support and resistance levels.
Is INHIBRX BIOSCIENCES INC (INBX) expected to grow?
The Revenue of INHIBRX BIOSCIENCES INC (INBX) is expected to decline by -60% in the next year. Check the estimates tab for more information on the INBX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy INHIBRX BIOSCIENCES INC (INBX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of INBX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of INBX, evaluating the profitability, health, valuation and growth aspects
- INHIBRX BIOSCIENCES INC (INBX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- INHIBRX BIOSCIENCES INC (INBX) Sales and EPS estimates to see what analysts future expectations are.
- INHIBRX BIOSCIENCES INC (INBX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- INHIBRX BIOSCIENCES INC (INBX) Insider and Institutional Ownership to learn about the owners and their transactions.
- INHIBRX BIOSCIENCES INC (INBX) Stock Chart to make your own analysis
- INHIBRX BIOSCIENCES INC (INBX) Latest news and press-releases to stay up to date.
Does INHIBRX BIOSCIENCES INC (INBX) stock pay dividends?
INBX does not pay a dividend.
What is the Price/Earnings (PE) ratio of INHIBRX BIOSCIENCES INC (INBX)?
The PE ratio for INHIBRX BIOSCIENCES INC (INBX) is 0.11. This is based on the reported non-GAAP earnings per share of 119.47 and the current share price of 12.56 USD. Check the full fundamental report for a full analysis of the valuation metrics for INBX.
What is the Short Interest ratio of INHIBRX BIOSCIENCES INC (INBX) stock?
The outstanding short interest for INHIBRX BIOSCIENCES INC (INBX) is 12.22% of its float. Check the ownership tab for more information on the INBX short interest.
INBX Technical Analysis
INBX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to INBX. While INBX seems to be doing ok healthwise, there are quite some concerns on its profitability.
INBX Financial Highlights
Over the last trailing twelve months INBX reported a non-GAAP Earnings per Share(EPS) of 119.47. The EPS increased by 2911.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 94684.72% | ||
| ROA | 737.7% | ||
| ROE | 919.96% | ||
| Debt/Equity | 0 |
INBX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 46% to INBX. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 2362.97% and a revenue growth -60% for INBX